Cargando…

Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma

IMPORTANCE: Administration of atezolizumab could be immunogenic and induce undesirable antidrug antibody (ADA) responses. This may interfere with atezolizumab-mediated actions, affecting drug clearance and serum concentration or inducing antibody neutralization. OBJECTIVE: To determine the clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Chan, Yang, Hannah, Kim, Ilhwan, Kang, Beodeul, Kim, Hyeyeong, Kim, Hyunho, Lee, Won Suk, Jung, Sanghoon, Lim, Ho Yeong, Cheon, Jaekyung, Chon, Hong Jae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585463/
https://www.ncbi.nlm.nih.gov/pubmed/36264560
http://dx.doi.org/10.1001/jamaoncol.2022.4733
_version_ 1784813500611166208
author Kim, Chan
Yang, Hannah
Kim, Ilhwan
Kang, Beodeul
Kim, Hyeyeong
Kim, Hyunho
Lee, Won Suk
Jung, Sanghoon
Lim, Ho Yeong
Cheon, Jaekyung
Chon, Hong Jae
author_facet Kim, Chan
Yang, Hannah
Kim, Ilhwan
Kang, Beodeul
Kim, Hyeyeong
Kim, Hyunho
Lee, Won Suk
Jung, Sanghoon
Lim, Ho Yeong
Cheon, Jaekyung
Chon, Hong Jae
author_sort Kim, Chan
collection PubMed
description IMPORTANCE: Administration of atezolizumab could be immunogenic and induce undesirable antidrug antibody (ADA) responses. This may interfere with atezolizumab-mediated actions, affecting drug clearance and serum concentration or inducing antibody neutralization. OBJECTIVE: To determine the clinical and immunological associations of highly elevated ADA levels with clinical outcomes after atezolizumab/bevacizumab (Atezo/Bev) treatment in patients with advanced hepatocellular carcinoma (HCC). DESIGN, SETTING, AND PARTICIPANTS: This cohort study prospectively enrolled 174 patients with advanced HCC treated with first-line Atezo/Bev (discovery cohort: 61 patients from 1 center; validation cohort: 113 patients from 4 centers). EXPOSURES: Serum ADA levels at pretreatment and 3 weeks (cycle 2 day 1 [C2D1]) were analyzed using competitive enzyme-linked immunosorbent assays. In addition, samples were subjected to serological and flow cytometric analyses. MAIN OUTCOMES AND MEASURES: Overall, ADA positivity was associated with treatment outcomes and T-cell functions. RESULTS: After excluding patients with inadequate samples, follow-up loss, or consent withdrawal, 132 patients (discovery cohort: 50 patients; 41 [82.0%] men; median age [IQR], 61 [55-70] years; validation cohort: 82 patients; 70 [85.4%] men; median age [IQR], 61 [53-68] years) were analyzed, and robust ADA (≥1000 ng/mL) responses at C2D1 were identified in 23 (17.4%) of the patients. Patients with progressive disease exhibited higher ADA levels (median [IQR], 65.2 [0-520.4] ng/mL) at C2D1 than in responders (median [IQR], 0 [0-117.5] ng/mL). In both discovery and validation cohorts, patients with high ADA levels at C2D1 were associated with a reduced response rate (discovery cohort: 34% vs 11%; validation cohort: 29% vs. 7%) and worse progression-free survival (discovery cohort: hazard ratio [HR], 2.84; 95% CI, 1.31-6.13; P = .005; validation cohort: HR, 2.52; 95% CI, 1.27-5.01; P = .006) and overall survival (discovery cohort: HR, 3.30; 95% CI, 1.43-7.64; P = .003; validation cohort: HR, 5.81, 95% CI, 2.70-12.50; P = .001) with Atezo/Bev compared with those with low ADA levels. In multivariable Cox regression, the clinical implication of high ADA levels persisted even after adjusting for various confounding factors and was most significant at 1000 ng/mL or greater. Compared with patients with low ADA levels, patients with high ADA levels exhibited reduced serum atezolizumab concentrations, impaired CD8-positive T-cell proliferation, and had decreased interferon-γ and tumor necrosis factor-α from CD8-positive T cells compared with patients with low ADA levels. CONCLUSIONS AND RELEVANCE: This cohort study found that highly elevated ADA levels at C2D1 may be associated with poor clinical outcomes in patients with advanced HCC treated with Atezo/Bev. High ADA levels may reduce atezolizumab exposure and attenuate the anticancer efficacy of the drug.
format Online
Article
Text
id pubmed-9585463
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-95854632022-11-04 Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma Kim, Chan Yang, Hannah Kim, Ilhwan Kang, Beodeul Kim, Hyeyeong Kim, Hyunho Lee, Won Suk Jung, Sanghoon Lim, Ho Yeong Cheon, Jaekyung Chon, Hong Jae JAMA Oncol Brief Report IMPORTANCE: Administration of atezolizumab could be immunogenic and induce undesirable antidrug antibody (ADA) responses. This may interfere with atezolizumab-mediated actions, affecting drug clearance and serum concentration or inducing antibody neutralization. OBJECTIVE: To determine the clinical and immunological associations of highly elevated ADA levels with clinical outcomes after atezolizumab/bevacizumab (Atezo/Bev) treatment in patients with advanced hepatocellular carcinoma (HCC). DESIGN, SETTING, AND PARTICIPANTS: This cohort study prospectively enrolled 174 patients with advanced HCC treated with first-line Atezo/Bev (discovery cohort: 61 patients from 1 center; validation cohort: 113 patients from 4 centers). EXPOSURES: Serum ADA levels at pretreatment and 3 weeks (cycle 2 day 1 [C2D1]) were analyzed using competitive enzyme-linked immunosorbent assays. In addition, samples were subjected to serological and flow cytometric analyses. MAIN OUTCOMES AND MEASURES: Overall, ADA positivity was associated with treatment outcomes and T-cell functions. RESULTS: After excluding patients with inadequate samples, follow-up loss, or consent withdrawal, 132 patients (discovery cohort: 50 patients; 41 [82.0%] men; median age [IQR], 61 [55-70] years; validation cohort: 82 patients; 70 [85.4%] men; median age [IQR], 61 [53-68] years) were analyzed, and robust ADA (≥1000 ng/mL) responses at C2D1 were identified in 23 (17.4%) of the patients. Patients with progressive disease exhibited higher ADA levels (median [IQR], 65.2 [0-520.4] ng/mL) at C2D1 than in responders (median [IQR], 0 [0-117.5] ng/mL). In both discovery and validation cohorts, patients with high ADA levels at C2D1 were associated with a reduced response rate (discovery cohort: 34% vs 11%; validation cohort: 29% vs. 7%) and worse progression-free survival (discovery cohort: hazard ratio [HR], 2.84; 95% CI, 1.31-6.13; P = .005; validation cohort: HR, 2.52; 95% CI, 1.27-5.01; P = .006) and overall survival (discovery cohort: HR, 3.30; 95% CI, 1.43-7.64; P = .003; validation cohort: HR, 5.81, 95% CI, 2.70-12.50; P = .001) with Atezo/Bev compared with those with low ADA levels. In multivariable Cox regression, the clinical implication of high ADA levels persisted even after adjusting for various confounding factors and was most significant at 1000 ng/mL or greater. Compared with patients with low ADA levels, patients with high ADA levels exhibited reduced serum atezolizumab concentrations, impaired CD8-positive T-cell proliferation, and had decreased interferon-γ and tumor necrosis factor-α from CD8-positive T cells compared with patients with low ADA levels. CONCLUSIONS AND RELEVANCE: This cohort study found that highly elevated ADA levels at C2D1 may be associated with poor clinical outcomes in patients with advanced HCC treated with Atezo/Bev. High ADA levels may reduce atezolizumab exposure and attenuate the anticancer efficacy of the drug. American Medical Association 2022-10-20 2022-12 /pmc/articles/PMC9585463/ /pubmed/36264560 http://dx.doi.org/10.1001/jamaoncol.2022.4733 Text en Copyright 2022 Kim C et al. JAMA Oncology. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Brief Report
Kim, Chan
Yang, Hannah
Kim, Ilhwan
Kang, Beodeul
Kim, Hyeyeong
Kim, Hyunho
Lee, Won Suk
Jung, Sanghoon
Lim, Ho Yeong
Cheon, Jaekyung
Chon, Hong Jae
Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma
title Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma
title_full Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma
title_fullStr Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma
title_full_unstemmed Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma
title_short Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma
title_sort association of high levels of antidrug antibodies against atezolizumab with clinical outcomes and t-cell responses in patients with hepatocellular carcinoma
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585463/
https://www.ncbi.nlm.nih.gov/pubmed/36264560
http://dx.doi.org/10.1001/jamaoncol.2022.4733
work_keys_str_mv AT kimchan associationofhighlevelsofantidrugantibodiesagainstatezolizumabwithclinicaloutcomesandtcellresponsesinpatientswithhepatocellularcarcinoma
AT yanghannah associationofhighlevelsofantidrugantibodiesagainstatezolizumabwithclinicaloutcomesandtcellresponsesinpatientswithhepatocellularcarcinoma
AT kimilhwan associationofhighlevelsofantidrugantibodiesagainstatezolizumabwithclinicaloutcomesandtcellresponsesinpatientswithhepatocellularcarcinoma
AT kangbeodeul associationofhighlevelsofantidrugantibodiesagainstatezolizumabwithclinicaloutcomesandtcellresponsesinpatientswithhepatocellularcarcinoma
AT kimhyeyeong associationofhighlevelsofantidrugantibodiesagainstatezolizumabwithclinicaloutcomesandtcellresponsesinpatientswithhepatocellularcarcinoma
AT kimhyunho associationofhighlevelsofantidrugantibodiesagainstatezolizumabwithclinicaloutcomesandtcellresponsesinpatientswithhepatocellularcarcinoma
AT leewonsuk associationofhighlevelsofantidrugantibodiesagainstatezolizumabwithclinicaloutcomesandtcellresponsesinpatientswithhepatocellularcarcinoma
AT jungsanghoon associationofhighlevelsofantidrugantibodiesagainstatezolizumabwithclinicaloutcomesandtcellresponsesinpatientswithhepatocellularcarcinoma
AT limhoyeong associationofhighlevelsofantidrugantibodiesagainstatezolizumabwithclinicaloutcomesandtcellresponsesinpatientswithhepatocellularcarcinoma
AT cheonjaekyung associationofhighlevelsofantidrugantibodiesagainstatezolizumabwithclinicaloutcomesandtcellresponsesinpatientswithhepatocellularcarcinoma
AT chonhongjae associationofhighlevelsofantidrugantibodiesagainstatezolizumabwithclinicaloutcomesandtcellresponsesinpatientswithhepatocellularcarcinoma